HK1043809A1 - Pharmaceutical composition for treating papillomavirus tumours and infection. - Google Patents

Pharmaceutical composition for treating papillomavirus tumours and infection.

Info

Publication number
HK1043809A1
HK1043809A1 HK02103266A HK02103266A HK1043809A1 HK 1043809 A1 HK1043809 A1 HK 1043809A1 HK 02103266 A HK02103266 A HK 02103266A HK 02103266 A HK02103266 A HK 02103266A HK 1043809 A1 HK1043809 A1 HK 1043809A1
Authority
HK
Hong Kong
Prior art keywords
infection
pharmaceutical composition
polypeptide
tumours
treating
Prior art date
Application number
HK02103266A
Other versions
HK1043809B (en
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1043809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of HK1043809A1 publication Critical patent/HK1043809A1/en
Publication of HK1043809B publication Critical patent/HK1043809B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition (A) for treating or preventing infections or tumours caused by papilloma virus (PV) contains as active ingredient: (a) ≥ 1 polypeptide (I) from the early region of PV and ≥ 1 polypeptide (II) from the late region of PV, or (b) ≥ 1 (I) and/or (II) plus a polypeptide (III) with immunostimulating activity. Also claimed are similar compositions containing vectors having inserts that encode (I)-(III).
HK02103266.9A 1996-07-30 2002-04-30 Pharmaceutical composition for treating papillomavirus tumours and infection HK1043809B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (en) 1996-07-30 1996-07-30 PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND PAPILLOMAVIRUS INFECTIONS

Publications (2)

Publication Number Publication Date
HK1043809A1 true HK1043809A1 (en) 2002-09-27
HK1043809B HK1043809B (en) 2004-12-03

Family

ID=9494633

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103266.9A HK1043809B (en) 1996-07-30 2002-04-30 Pharmaceutical composition for treating papillomavirus tumours and infection

Country Status (12)

Country Link
EP (2) EP1149910B1 (en)
JP (2) JP4070815B2 (en)
AT (2) ATE205881T1 (en)
AU (1) AU736720B2 (en)
CA (1) CA2234263C (en)
DE (2) DE69706825T3 (en)
DK (2) DK1149910T3 (en)
ES (2) ES2215805T3 (en)
FR (1) FR2751879B1 (en)
HK (1) HK1043809B (en)
PT (2) PT862634E (en)
WO (1) WO1998004705A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1089758A1 (en) * 1998-06-26 2001-04-11 Aventis Pasteur Mucosal targeting immunisation
US8058049B2 (en) * 2006-06-20 2011-11-15 Transgene S.A. Process for producing poxviruses and poxvirus compositions
HUE025015T2 (en) 2009-01-20 2016-04-28 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
KR20110138354A (en) 2009-03-24 2011-12-27 트랜스진 에스.에이. Biomarker for monitoring patients
PL2419728T3 (en) 2009-04-17 2014-05-30 Transgene Sa Biomarker for monitoring patients
EP2429579A1 (en) 2009-05-12 2012-03-21 Transgene SA Immortalized avian cell lines and use thereof
US9261512B2 (en) 2009-07-10 2016-02-16 Transgene, S.A. Biomarker for treating cancer patients
WO2011009613A1 (en) 2009-07-21 2011-01-27 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
CA2969034A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
FR3042121A1 (en) * 2015-10-08 2017-04-14 Jean-Marc Limacher ANTI-TUMOR COMPOSITION
JP2020519666A (en) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US20210187100A1 (en) 2018-09-06 2021-06-24 Bavarian Nordic A/S Storage Improved Poxvirus Compositions
AU2021233167A1 (en) 2020-03-12 2022-09-22 Bavarian Nordic A/S Compositions improving poxvirus stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (en) * 1989-03-06 1993-12-17 Transgene Sa PHARMACEUTICAL COMPOSITION, USEFUL AS A PREVENTIVE OR CURATIVE AGAINST TUMORS INDUCED BY PAPILLOMAVIRUS
AU650868B2 (en) † 1990-03-20 1994-07-07 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (HPV) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
EP1298211B1 (en) * 1991-07-19 2006-07-12 The University Of Queensland Polynucleotide segment of HPV16 Genome
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (en) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc PSEUDO-PARTICLES VIRALES USEFUL AS A VECTOR OF NUCLEIC ACID DELIVERY

Also Published As

Publication number Publication date
FR2751879B1 (en) 1998-10-30
PT1149910E (en) 2004-09-30
ES2163795T5 (en) 2006-07-16
ATE205881T1 (en) 2001-10-15
AU736720B2 (en) 2001-08-02
EP0862634A1 (en) 1998-09-09
EP0862634B2 (en) 2006-03-01
ES2163795T3 (en) 2002-02-01
DK0862634T3 (en) 2002-01-21
EP0862634B1 (en) 2001-09-19
JP2007254474A (en) 2007-10-04
JP4070815B2 (en) 2008-04-02
EP1149910A1 (en) 2001-10-31
DE69706825D1 (en) 2001-10-25
WO1998004705A1 (en) 1998-02-05
CA2234263A1 (en) 1998-02-05
DE69728914T2 (en) 2005-04-07
PT862634E (en) 2002-03-28
DK0862634T4 (en) 2006-05-08
HK1043809B (en) 2004-12-03
JP4198735B2 (en) 2008-12-17
CA2234263C (en) 2009-10-13
DK1149910T3 (en) 2004-08-02
JP2000500662A (en) 2000-01-25
EP1149910B1 (en) 2004-04-28
DE69706825T3 (en) 2006-08-24
ATE265535T1 (en) 2004-05-15
FR2751879A1 (en) 1998-02-06
DE69706825T2 (en) 2002-05-02
DE69728914D1 (en) 2004-06-03
AU3855297A (en) 1998-02-20
ES2215805T3 (en) 2004-10-16

Similar Documents

Publication Publication Date Title
HK1043809A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection.
TW218874B (en)
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
AU6783698A (en) Polyaromatic antiviral compositions
YU24402A (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicamt and pharmaceutical preparations containing said compounds
KR0180256B1 (en) Bpc peptides, their preparation and use
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
CA2027814A1 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
CA2263846A1 (en) Novel pyranoside derivatives
EP1074264A4 (en) Neovascularization inhibitors
MY101169A (en) Novel phenylureas
CA2030344A1 (en) Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
ZA953584B (en) Novel active peptide and its preparation
AU6722498A (en) Disubstituted biphenyloxazolines
TW249802B (en)
WO1998023574A8 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
MY106961A (en) Antiviral tetrahydroimidazo[1,4] benzodiazepines
CA2188508A1 (en) Gonadotropins with non-native disulfide bridges
RU94019328A (en) α- HETEROARILOXYMETYLKETONES, PHARMACEUTICAL COMPOSITION, INHIBITING INTERLEUKIN-1 - β-PROTEASIS
CA2022081A1 (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
MX9801104A (en) Remedy for coxsackie virus b infection.
CA2234611A1 (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160729